Comparing 2 hypotheses side-by-side
During early amyloid nucleation (Braak I-II), compensatory DNMT1 upregulation maintains BDNF promoter methylation and synaptic gene expression. This compensation fails at a specific transition point marked by CSF p-tau217/181 elevation, after which DNMT1 activity becomes irreversibly dysregulated. Restoration before this window preserves synaptic resilience.
**Molecular Mechanism and Rationale** DNA methyltransferase 1 (DNMT1) serves as the primary maintenance methyltransferase in mammalian cells, responsible for preserving DNA methylation patterns during cell division by adding methyl groups to hemimethylated CpG dinucleotides. In the context of neurodegeneration, DNMT1 dysregulation leads to aberrant hypermethylation of critical neuronal genes, particularly at promoter regions containing CpG islands. This pathological methylation silences neuropr
| Dimension | DNMT1 Compensation Window Duri | DNMT1-Targeting Antisense Olig |
|---|---|---|
| Mechanistic | 0.520 | 0.300 |
| Evidence | 0.600 | 0.300 |
| Novelty | 0.700 | 0.600 |
| Feasibility | 0.420 | 0.400 |
| Impact | 0.580 | 0.300 |
| Druggability | 0.380 | 0.500 |
| Safety | 0.350 | 0.200 |
| Competition | 0.600 | 0.400 |
| Data | 0.550 | 0.400 |
| Reproducible | 0.580 | 0.300 |
No evidence citations yet
No evidence citations yet
4 rounds · quality: 0.68
# Therapeutic Hypotheses: Optimal Epigenetic Reprogramming Window in Preclinical AD --- ## Hypothesis 1: DNMT1 Compensation Window During Synaptic Resilience Phase **Title:** *The Pre-Symptomatic D...
# Critical Evaluation of Epigenetic Reprogramming Window Hypotheses ## Overview These seven hypotheses propose overlapping but mechanistically distinct temporal windows for epigenetic intervention i...
# Expert Assessment: Epigenetic Reprogramming Window Hypotheses for Preclinical AD ## Executive Summary These seven hypotheses represent sophisticated integration of chromatin biology with AD pathop...
{"ranked_hypotheses":[{"title":"HDAC2 Phospho-Lock Window for Synaptic Gene Silencing","description":"A narrow pre-symptomatic window exists (CDR 0) when HDAC2 enrichment at synaptic gene promoters re...
4 rounds · quality: 0.88
# Novel Therapeutic Hypotheses: Epigenetic Clocks and Neurodegeneration ## Hypothesis 1: TET2-Mediated Demethylation Rejuvenation Therapy **Description:** Targeted overexpression of TET2 methylcytosi...
# Novel Therapeutic Hypotheses: Epigenetic Clocks and Neurodegeneration ## Hypothesis 1: TET2-Mediated Demethylation Rejuvenation Therapy **Description:** Targeted overexpression of TET2 methylcytosi...
# Critical Evaluation of Epigenetic Clock and Neurodegeneration Hypotheses ## Hypothesis 1: TET2-Mediated Demethylation Rejuvenation Therapy ### Specific Weaknesses: 1. **Lack of specificity**: TET2...
# Critical Evaluation of Epigenetic Clock and Neurodegeneration Hypotheses ## Hypothesis 1: TET2-Mediated Demethylation Rejuvenation Therapy ### Specific Weaknesses: 1. **Lack of specificity**: TET2...
Curated mechanism pathway diagrams from expert analysis
graph TD
A["DNMT1<br/>Overexpression"]
B["Aberrant CpG<br/>Hypermethylation"]
C["BDNF Gene<br/>Silencing"]
D["CREB1 Gene<br/>Silencing"]
E["EGR1 Gene<br/>Silencing"]
F["Reduced Synaptic<br/>Plasticity"]
G["Neuronal<br/>Death"]
H["Chronic<br/>Neuroinflammation"]
I["Oxidative<br/>Stress"]
J["DNMT1-Targeting<br/>Antisense Oligonucleotide"]
K["PCNA/DMAP1/EZH2<br/>Cofactor Disruption"]
L["DNA Methylation<br/>Pattern Reset"]
M["Neuroprotective Gene<br/>Reactivation"]
N["Cognitive Function<br/>Recovery"]
O["Neurodegeneration<br/>Progression"]
A -->|"Promoter targeting"| B
B -->|"Transcriptional silencing"| C
B -->|"Transcriptional silencing"| D
B -->|"Transcriptional silencing"| E
C -->|"Loss of neurotrophic support"| F
D -->|"Impaired survival signaling"| G
E -->|"Reduced plasticity genes"| F
F -->|"Synaptic dysfunction"| O
G -->|"Cell loss"| O
H -->|"Inflammatory signaling"| A
I -->|"Stress response"| A
J -->|"DNMT1 knockdown"| K
J -->|"Methyltransferase inhibition"| L
K -->|"Cofactor disruption"| L
L -->|"Epigenetic reprogramming"| M
M -->|"BDNF/CREB1/EGR1 restoration"| N
classDef pathology fill:#ef5350
classDef therapy fill:#81c784
classDef outcome fill:#ffd54f
classDef molecular fill:#ce93d8
classDef normal fill:#4fc3f7
class A,B,F,G,H,I,O pathology
class J,K,L,M therapy
class N outcome
class C,D,E molecular